lisocabtagene maraleucel,ibrutinib,venetoclax
Bms,Roche,Abbvie,janssen
['lymsm', 'cll 004', 'liso-cel', 'transcend cll 004', 'transcend,(-nhl-001),(-nhl 001),(-nhl001),(-nhl-006),(-nhl 006),(-nhl006),(-pilot-017006),(-pilot017006),(-pilot 017006)', 'cll']
transcend cll 004 liso-cel #17icml:
- 87 pts (49 with pd after btk &amp; ven) at dl2
- 63% umrd in blood
- mdor 35 mo in full cohort &amp; btk/ven pd cohort
- more high grade crs/icans than other liso-cel trials (1 gr5 hlh)
good option after ven/btk. discrepancy between mrd &amp; orr? #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈